Swiss National Bank’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Swiss National Bank’s Portfolio SCLN Stock Details SCLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-81,600	Closed	-$898K	–	2531
2017 Q2	$898K	Hold	81,600	–	–	﹤0.01%	2123
2017 Q1	$800K	Hold	81,600	–	–	﹤0.01%	2160
2016 Q4	$881K	Hold	81,600	–	–	﹤0.01%	2113
2016 Q3	$836K	Sell	81,600 -4,900	-6%	-$53.4K	﹤0.01%	2084
2016 Q2	$1.13M	Hold	86,500	–	–	﹤0.01%	1885
2016 Q1	$922K	Buy	86,500 +14,200	+20%	+$126K	﹤0.01%	1944
2015 Q4	$665K	Hold	72,300	–	–	﹤0.01%	2100
2015 Q3	$502K	Buy	72,300 +7,000	+11%	+$59.9K	﹤0.01%	2181
2015 Q2	$641K	Buy	65,300 +3,400	+5%	+$31K	﹤0.01%	2084
2015 Q1	$548K	Hold	61,900	–	–	﹤0.01%	2129
2014 Q4	$542K	Buy	61,900 +2,700	+5%	+$21.9K	﹤0.01%	2127
2014 Q3	$408K	Hold	59,200	–	–	﹤0.01%	2207
2014 Q2	$311K	Hold	59,200	–	–	﹤0.01%	2376
2014 Q1	$269K	Buy	59,200 +7,300	+14%	+$35.3K	﹤0.01%	2361
2013 Q4	$262K	Hold	51,900	–	–	﹤0.01%	2321
2013 Q3	$263K	Hold	51,900	–	–	﹤0.01%	2276
2013 Q2	$257K	Buy	+51,900	New	+$247K	﹤0.01%	2284

Other funds holding SCLN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Swiss National Bank's SCLN Position: Q3 2017 in Review

Swiss National Bank sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q3 2017, closing a stake of 81,600 shares — an estimated $898K sold.

Swiss National Bank first reported a position in SCLN in Q2 2013 and held it in 17 quarters. The position peaked at $1.13M in Q2 2016. 129 funds tracked by Wall St. Rank hold SCLN as of Q3 2017.

Swiss National Bank reported no remaining Sciclone Pharmaceuticals Inc position as of Q3 2017 after selling out during the quarter.
Swiss National Bank sold 81,600 Sciclone Pharmaceuticals Inc shares in Q3 2017, an estimated $898K.
Swiss National Bank first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 17 quarters.
Swiss National Bank's Sciclone Pharmaceuticals Inc position peaked at $1.13M in Q2 2016.
129 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q3 2017.

Based on Swiss National Bank's 13F filing for Q3 2017, filed 3 Nov 2017.